Skip to search boxSkip to navigationSkip to main content

Short-, mid-, and long-term complications after multisystem inflammatory syndrome in children over a 24-month follow-up period in a hospital in Lima-Peru, 2020–2022

  • Giancarlo Alvarado-Gamarra(corresponding author)
    ,
  • Matilde Estupiñan-Vigil
    ,
  • Raquel Garcés-Ghilardi
    ,
  • Jesús Domínguez-Rojas
    ,
  • Olguita del Águila
    ,
  • Katherine Alcalá-Marcos
*Corresponding author for this work
  • Hospital Nacional Edgardo Rebagliati Martins, EsSalud
    ,
  • REDECS
    ,
  • Instituto de Investigación Nutricional
    ,
  • Instituto Nacional Cardiovascular Carlos Alberto Peschiera Carrillo, EsSalud
    ,
  • ,
  • Vanderbilt University Medical Centre
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Article number

1232522

Journal (Volume, Issue Number)

Frontiers in Pediatrics (Volume 11)

Publication milestones

  • Published - 08/02/2023

Publication status

Published - 08/02/2023

Publication IDs

  • Scopus: 85178967101

Abstract

Objective: To determine the short-, mid-, and long-term complications after multisystem inflammatory syndrome in children (MIS-C) over a 24-month follow-up period in a hospital in Lima, Peru, 2020–2022, and to explore differences according to the immunomodulatory treatment received and type of SARS-CoV-2 virus circulating. Methods: Ambispective 24-month follow-up study in children <14 years of age diagnosed with MIS-C at the Hospital Nacional Edgardo Rebagliati Martins (HNERM). Results: A total of 62 children were admitted with MIS-C. The most common short-term complications and serious events were intensive care unit (ICU) admission, invasive mechanical ventilation (IMV) due to respiratory failure, and shock; predominantly during the second pandemic wave (lambda predominance) and in children that received intravenous immunoglobulin (IVIG) plus a corticosteroid. Two patients died during the first wave due to MIS-C. During prospective follow-up (median of 24 months; IQR: 16.7–24), only 46.7% of patients were followed for >18–24 months. Of the total, seven (11.3%) patients were identified with some sequelae on discharge. Among the 43 remaining children, sequelae persisted in five (11.6%) cases (neurological, hematological, and skin problems). Six patients (13.9%) presented with new onset disease (hematologic, respiratory, neurological, and psychiatric disorders). One patient died due to acute leukemia during the follow-up period. None of them were admitted to the ICU or presented with MIS-C reactivation. Two patients presented persistence of coronary aneurysm until 8- and 24-month post-discharge. Conclusion: In our hospital, children with MIS-C frequently developed short-term complications and serious events during the acute phase, with less frequent complications in the mid- and long-term. More studies are required to confirm these findings.

Funding Details

GA was supported by the Kaelin Award in Health Sciences-protocols 2021 grant from the “Instituto de Evaluación e Investigación de Tecnologías en Salud” (IETSI), EsSalud, Peru. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Acknowledgments We thank the patients and their families, and the IETSI, EsSalud, Peru for their financial support of our project.
FundersFunding numbers
EsSalud
-
IETSI
-
Instituto de Evaluación de Tecnologías en Salud en Investigación
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Mentions
1
Captures
7
Citations
3